Rick Powers

Medicine · Health Sciences

4h-index458citations15works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(6), HER2/EGFR in Cancer Research(4), Prostate Cancer Treatment and Research(3), Monoclonal and Polyclonal Antibodies Research(3), Chronic Lymphocytic Leukemia Research(3)

Publications15 total

Supplementary Figure Legends from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Table S1 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Table S1 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Figure Legends from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Figures S1-S7 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Data from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Data from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Figures S1-S7 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
Cancer Research·2018· 189 cited
ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment
European Journal of Cancer·2016· 2 cited
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
PubMed·2006· 116 cited
Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer
Molecular Cancer Therapeutics·2004· 85 citedOpen Access
Identification and validation of anti-TMEFF2-Auristatin E conjugated antibodies in the treatment of prostate cancer
Journal of Clinical Oncology·2004
Identification and validation of anti-TMEFF2-Auristatin E conjugated antibodies in the treatment of prostate cancer
Journal of Clinical Oncology·2004· 1 cited
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
PubMed·2003· 65 cited

Frequent Co-authors

Sonia G. Tanlimco(10), Jonathan A. Hickson(10), Melvin Fox(10), Mien Sho(10), Tamar Uziel(10), Thomas McGonigal(10), Josue Samayoa(10), Diane Hollenbaugh(10), Kurt Gish(10), Susan E. Morgan-Lappe(10), Eric D. Hsi(10), James W. Purcell(9), Lisa Durkin(9), Subashri Kumar(9), Joann P. Palma(9), Debra T. Chao(9), Kelly Foster(8), Sasmita Mishra(8), Dong Zhang(5), Vanitha Ramakrishnan(5)